New combo therapy aims to save tiny lungs
NCT ID NCT04545866
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether adding budesonide (an anti-inflammatory) to standard surfactant treatment helps extremely preterm babies avoid chronic lung disease or death. About 642 infants born before 29 weeks or weighing under 1000 grams will receive either the combo or surfactant alone within 48 hours of birth. The goal is to see if the combo reduces lung damage and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
budesonide (an anti-inflammatory drug) combined with surfactant (a lung lubricant)
What this could lead to
If it works, this could reduce the risk of chronic lung disease or death in extremely premature babies.
What could go wrong
This is a single Phase 3 trial; results may not apply to all preterm infants. The combination could have side effects like infection or impaired lung development.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREMATURITY; EXTREME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brown University - Women and Infants Hospital of Rhode Island
Providence, Rhode Island, 02905, United States
-
Case Western Reserve University, Rainbow Babies and Children's Hospital
Cleveland, Ohio, 44106, United States
-
Cincinnati Children's Medical Center
Cincinnati, Ohio, 45267, United States
-
Duke University
Durham, North Carolina, 27710, United States
-
Emory University
Atlanta, Georgia, 30303, United States
-
Northwestern Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611, United States
-
RTI International
Durham, North Carolina, 27705, United States
-
Research Institute at Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
Sharp Mary Birch Hospital for Women & Newborns
San Diego, California, 92123, United States
-
Stanford University
Palo Alto, California, 94304, United States
-
University of Alabama
Birmingham, Alabama, 35249-7335, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Mississippi Medical Center - Children's of Mississippi
Jackson, Mississippi, 39216, United States
-
University of New Mexico
Albuquerque, New Mexico, 87131, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Rochester
Rochester, New York, 14642, United States
-
University of Texas Health Science Center at Houston
Houston, Texas, 77030, United States
-
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, 75235, United States
-
University of Utah
Salt Lake City, Utah, 84108, United States